OTC Markets OTCPK - Delayed Quote USD

Bayer Aktiengesellschaft (BAYRY)

Compare
8.22 -0.01 (-0.12%)
At close: October 4 at 4:00 PM EDT
Loading Chart for BAYRY
DELL
  • Previous Close 8.23
  • Open 8.16
  • Bid 8.21 x 40700
  • Ask 8.23 x 40000
  • Day's Range 8.16 - 8.23
  • 52 Week Range 6.82 - 11.96
  • Volume 79,747
  • Avg. Volume 807,182
  • Market Cap (intraday) 32.411B
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -0.36
  • Earnings Date Nov 12, 2024
  • Forward Dividend & Yield 0.03 (0.36%)
  • Ex-Dividend Date Apr 29, 2024
  • 1y Target Est 22.11

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

www.bayer.com

96,567

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYRY

View More

Performance Overview: BAYRY

Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYRY
10.58%
DAX PERFORMANCE-INDEX
14.14%

1-Year Return

BAYRY
27.98%
DAX PERFORMANCE-INDEX
26.75%

3-Year Return

BAYRY
34.79%
DAX PERFORMANCE-INDEX
26.16%

5-Year Return

BAYRY
42.75%
DAX PERFORMANCE-INDEX
60.34%

Compare To: BAYRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYRY

View More

Valuation Measures

Annual
As of 10/4/2024
  • Market Cap

    32.31B

  • Enterprise Value

    67.94B

  • Trailing P/E

    --

  • Forward P/E

    5.52

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.62

  • Price/Book (mrq)

    0.82

  • Enterprise Value/Revenue

    1.31

  • Enterprise Value/EBITDA

    6.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.69%

  • Return on Assets (ttm)

    3.71%

  • Return on Equity (ttm)

    -3.45%

  • Revenue (ttm)

    47.11B

  • Net Income Avi to Common (ttm)

    -1.27B

  • Diluted EPS (ttm)

    -0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.02B

  • Total Debt/Equity (mrq)

    129.94%

  • Levered Free Cash Flow (ttm)

    6.26B

Research Analysis: BAYRY

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 11.14B
Earnings -34M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.60
22.11 Average
8.22 Current
50.18 High
 

Company Insights: BAYRY

Research Reports: BAYRY

View More
  • Bayer Earnings: Steady Growth Supported by New Drug Launches Offsetting Generic Pressures

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer Earnings: Solid Results Aided by Litigation Win, Cost-Cutting, and Innovation Advancements

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer Earnings: Expected Cost Pressures Lead to a Valuation Cut, but Stock Remains Undervalued

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer: Dividend Cut Increases Flexibility to Reduce Debt, Improve Operations, and Expand Innovation

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     

People Also Watch